Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Nov 06 | 2023New Empa + BI 690517 Ph2 CKD Data; Madrigal and Vertex Q3 ‘23 Earnings; MannKind Completes INHALE-3 Enrollment; November CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Other, SGLT2i Nov 03 | 2023Novo London Q3 ’23 Earnings; Terns Doses First Patient in Ph1 Obesity Trial; Ionis, Regeneron, and Dario Q3 ’23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 02 | 2023Insulet Q3 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Nov 02 | 2023Lilly Q3 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Nov 02 | 2023SELECT Receives Priority Review; High-dose Oral Sema Delayed; Novo Q3 ’23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 02 | 2023Sibionics Receives GS1 CGM CE Mark; Silence Therapeutics Announces Positive Ph1 Lp(a) Results; Lilly Initiates Another Oral GLP-1RA Ph3 Trial; Tandem and Amarin Q3 ‘23 Earnings; Lexicon Expands Inpefa Access; Dario Launches BGM Compatible With iPhone 15; Abbott, Insulet, and BI/Lilly Announce National Diabetes Awareness Month InitiativesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Nov 01 | 2023Lilly Acquires Rights to Gene Editing Programs for CVD; Know Labs to Present at Bernstein CGM Disruptors Conference; Pharmacies Struggle to Afford GLP-1RAs; Sigrid Secures Funding for Diabetes/Obesity; Porosome Announces New T1DM/T2DM Treatment Approach; Pfizer and Amgen Q3 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Oct 30 | 2023Sernova Announces Conformal Coating Technology Advancements; Lilly and BioAge to Initiate Ph2 Tirzepatide Combo Trial; Lilly Partners with Redwire for Cardiometabolic Space Research; EMA Finds No Link Between GLP-1RAs and Thyroid Cancers; Sanofi Invests in MeiraGTx for Gene Regulation TechnologyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 27 | 2023Sanofi Q3 ’23 Earnings; Additional Sernova Cell Pouch Data; GSK Initiates New Ph2a NASH StudyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery Oct 27 | 2023Dexcom Q3 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Oct 26 | 2023Altimmune’s Pemvidutide Receives Fast Track Designation in NASH; New Diamyd T1DM Results; Viking and Merck Q3 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other Oct 26 | 2023FDA Accepts Vadadustat NDA Resubmission; Glooko Appoints Enrique Conterno to Board of Directors; Novo Launches “iCARE4CVD”; Todd Hobbs Joins Diasome as CMO; Teladoc Q3 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Oct 25 | 2023Novartis Q3 ’23 Earnings; Counterfeit Ozempic Hospitalizes Patients in Austria; NexImmune Extends Partnership with Yale and JDRFPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Oct 23 | 2023Insulet Receives 510(k) Clearance for O5 iPhone App; Viking Completes Enrollment for Ph2 GLP-1/GIP RA Studyin ObesityPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 20 | 2023Lilly Hires CordenPharma to Make Mounjaro; Diamyd Booster ResultsPurchase Blast
$599
Posted in: Other, SGLT2i Oct 19 | 2023Novo Partners with GE Healthcare for T2DM/Obesity; Cytokinetics’ Cardiac Myosin Inhibitor Programs Update; New Ph3 Dapa+Zibotentan Combination Trial in CKD and High ProteinuriaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Oct 18 | 2023Abbott Q3 ’23 Earnings; Tzield PROTECT Data at ISPAD 2023; Viking GLP-1/GIP RA Ph1 Data at ObesityWeekPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, Other, SGLT2i Oct 17 | 2023Novo to Displace Metformin as 1L T2DM Treatment?; Zealand Presents Amylin Analog Data at ObesityWeek; JNJ Q3 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 16 | 2023SURMOUNT-3 Presented at ObesityWeek; Novo Adds to Its CKD Pipeline; Carmot Presents T2DM/Obesity Results; Better Therapeutics Launches AspyreRx for T2DMPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 13 | 2023Novo Raises 2023 Guidance; Glucotrack’s Implantable CGM Preclinical ResultsPurchase Blast